secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0001213900-24-016737
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake gets FDA & EMA support for Phase 3 sonelokimab in hidradenitis suppurativa
--------------------------------------------------------------------------------

- FDA and EMA both support Phase 3 design for sonelokimab (SLK) in HS; trial named VELA.
- Phase 3 will enroll 800 patients; single 120mg dose vs placebo over 16 weeks; primary endpoint HiSCR75.
- First patient randomization expected Q2 2024; primary endpoint readout mid-2025.
- Combined Phase 2 and Phase 3 data to support BLA and EU marketing application.
- End-of-Phase 2 meeting for PsA with FDA expected Q2 2024; Phase 3 start Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000121390024016737/0001213900-24-016737-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000121390024016737/ea0200697-8k_moonlake.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-016737

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer